Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Or worthless. Company will trade at face value of whatever cash remains in the bank and we know Missling is expensive overhead as well of other non value added staff members. Ahem fugly bitxhes he surrounds himself with.
I agree with you about the mechanical computer trading system... but I believe it's still possible to watch and see what those trading bots are doing, with their trading, algorithmic movements to math targets, it's got to be running on some programmed data... makes decisions based on math algos, etc, you can still examine all of the price action and find patterns and targets. If anything, it might even be a more precise process because it's computer programs, programmed to trigger by design. I believe the trading program includes Fibonacci math among other equations. I like the data that you watch. As well.
I wish that I could “keep the faith”, but when your CEO acts shady and obtuse like Missling, it’s hard to believe in the product or leadership.
We often talk about binary moments with pharmas—in this case, either Missling produces results or the lawsuits will bankrupt the company.
"IMO - it's only a matter of time." You know what's also only a matter of time - eventual death. Will any of us here live to see AVXL a $4 stock again? It's one of the biggest pieces of schitt I've ever invested in and I'm an expert at investing in schitt.
In past decades, TA carried more weight.
The market is now controlled by wash trading AI bots.
You have to invest in fundamentals and hang in there to win.
Don't count Anavex out. They are getting positive trial responses.
IMO - it's only a matter of time.
Flip a coin—never did find much value in TA. It is like driving a car using a rear view mirror. Not much predictive value, other than stating the obvious that it may go up or down. It might rain tomorrow, or it might be sunny.
Fren, you have to do a better job reading the details of my commentary. Understand what I describe about the price action as it tumbles down to a target, as it bounces up, or doesn't bounce up, if it bounces, where does it hit resistance, did I forecast that resistance zone, you have to watch the price action, and see where the resistance zone is, and the support steps, and the trade targets. Today was a target step at 3.25. Watch what price does tomorrow, and we'll talk again.
LOL.
Beating a dead horse man…
Yes, clown...look at my response. Pay attention to what I describe. You can do it. I have faith in you. I describe the puzzle game. In clear detail.
Watch the resistance overhead now. 👍️
Tom I hate to be rude but...could you not just say the price could go up or down?
Yep, pretty pitiful. The market is valuing this drug platform as nearly “worthless.”
At Dec. 31, Anavex had $143 million in cash and 82 million shares outstanding. That’s $1.80 a share in cash at year end. The stock closed today at $3.39. That means the market is valuing Anavex’s pipeline, technology, and patents at $1.59 a share.
Not exactly a ringing endorsement for what the WGTers believe will be the world’s first trillion dollar drug.
Look at your response.
But you are seeing things.
Price action today....
Puked out at the open to finish yesterday's tumble... hit the 3.25 target step and bounced back to the 3.40 , let's call it first resistance now, and then finished the day hanging there. What could we see tomorrow to finish the week... well, finishing the week doesn't necessarily mean finishing the wave pattern. And this one now looks to me like it has a chance to keep playing out for several more days , developing the chart pattern. By this I mean ... starting with the spike pivot low at 3.25, it bounced back 20 cents and made an impression. The 'spike tail' it made on the candle often happens in a "bottoming" pattern. Maybe a few similar spikes to come. But in the overall downwave, we must wait and now watch what happens at the resistance zone, like what's happened since the 6.80 peak, the bounces hit resistance, roll over, and tumble down lower. This pattern hasn't stopped yet. Now I watch the next resistance from 3.45-3.55-3.60 area to see if selling force attacks there, and sends the price tumbling down to lower lows and the main target around 3.00. I like 2.90/2.80 as well. But step by step, it bleeds down to develop a finished Bottom, until Good news stops the bleeding down game. Here at resistance 3.50, a balance point, the next key trade targets look like 4 dollars or 3 dollars. The downwave move would look on the chart like 3.85 to 3.00 and the 'upwave' move would be 3.25 to 4 bucks.
Do you think 3.25 will print as the major cycle Bottom? Mmmmm..... 🤔 ... 🎱...🤡 ... 🧐 ... I dunno... I'm still thinking 3 dollars, 2.90,2.80... let's see how it goes. First... we watch the resistance overhead, and if price gets whacked down from there.That would be a fair clue.
A FOUR YEAR LOW. We haven't seen the stock this low since BEFORE the $150 million cash infusion. In other words the market has it figured out that all of their drugs are basically useless.
Nice close!!
We are just under 46 cents on the 10DMA...It still drops about 10 cent a day...On the bright side, it may only take another week before we close above it!
Target is still 2.90...Then we go to WGT and ride for huge gains back to where we are today! Hee Haw!! Can't wait....
I'll give you all a break and come back next week.
🤡 🧐 ....I see Everything, clown.
How does the fundamental and business picture look to you? I actually read and value your input among the fundies. I try to learn what you all talk about.
..............................
If price continues lower, toward 3.00, and lower, are you buying any?
Thats a 10-4.
All hands on deck....It's time for lift off!
1249 here we come. WGT!! Chris for World Leader....They don't come any brighter!
I love this board!!! It makes me laugh....Laughter is good for the mind, soul and body!!
Read my reply to Xena's post.
Sure, whatever you say.
Read your question and then the response. Hint: first sentence.
Anyone have the new institutional holding numbers due out yesterday?
TIA
Your posts have become total garbage.
What about the stock?
Not anymore...Hold and buy more!!!
No point selling at this level...Downside is only 3.30 and upside is 1,245.70!!
I’ll accept that non-answer for what it is. A deflection.
Yes Anavex did not met all endpoints as defined at the time of their Dec 22 fumbled topline presentation, when Anavex claimed they were met. That was always clear and is now established by Missling himself recently admitting that ADL was not significant.
Since then alternative ways of presenting the data from the P2b/3 have been used and may indeed be approvable. The EMA submission if/when finalised, submitted and validated may then in turn lead to approval. That outcome will not be known for another year or so.
If Anavex is still discussing data interpretation with the FDA, of course they won't be discussing it publicly.
NO, TGD won't release the full data for nothing. Its sitting on his computer calculating away and the red light is still flickering. This year too.
I think the trajectory is established now. The trend is clearly not my friend. TGD has nothing to say except the usual dog and pony.
My Friend asks if she is going to be asking, "Is AVXhell still still going to cut in half again after sagging to $1.70 in three months?" Or does She cash out now and buy back in in 35 days if the trajectory changes? Asking for a friend.
Spend sometime thinking about it. It could help you become a better biotech investor or just in general investing in public listed companies based required information disclosures.
(P = 0.0226) for ADAS-Cog13 is the correct p value for the Phase 2b/3 score for ADAS-COG13.
2.26 out of 100 chance of being due to pure bad luck or a 97.74 out of 100 chance that the p value for ADAS-Cog13 is correct.
97.74% is a fairly good score.
Good luck and GOD bless,
Hosai, check your numerals ... one too many or one too few.
Peace,
powerwalker
I don’t understand your answer. The company has reiterated several times that all endpoints were met.
So I asked Google AI...
Can alternative endpoints be selected after a drug trial is finished?
Yes, some clinical trials have successfully changed endpoints after the trial has begun. The original primary endpoint may be changed if new knowledge or events make it no longer appropriate. For example, the Post-CABG (Post Coronary Artery Bypass Graft) trial did not identify a primary endpoint when it was designed, but instead planned to compare changes in lipid deposition over five years.
Endpoints are outcome measures used to address the objectives of a clinical trial. The primary endpoint is the most important outcome and is used to assess the primary objective of a trial (e.g., the variable used to compare the effect difference of two treatment groups). A fundamental principle in the design of randomized trials involves setting out in advance the endpoints that will be assessed in the trial [1], as failure to prespecify endpoints can introduce bias into a trial and creates opportunities for manipulation. However, sometimes new information may come to light that could merit changes to endpoints during the course of a trial. This new information might include, for example, results from other trials or identification of better biomarkers or surrogate outcome measures. Such changes can allow incorporation of up-to-date knowledge into the trial design. However, changes to endpoints can also compromise the scientific integrity of a trial. Here I discuss some of the issues and decision-making processes that should be considered when evaluating whether to make changes to endpoints, and discuss the documentation and reporting of clinical trials that have revised endpoints.
Only if as an investor in a public company you can rely on public information that the company is responsible for updating, such as that on clinicaltrials.gov and in their presentations.
Do we know for certain yet what the endpoints were?
Different diseases with different disease pathways. Not an apples to apples comparison.
If the Results for Rett weren't significant ao why would they be for Alz
It was and is lying to state all endpoints were met. A strange thing to say, when also at the same time saying they did't have all the data in until last minute. It was clear all along to experienced biotech investors that ADL was not stat sig.
Oh, you know it will? When?
But of course you HAVE set a timeline in your mind and just watch
Chris is full of shit
You seem to have developed quite an obsession with trying to convince people to sell. How many posts per day do you make at this point? 20?
Any idiot knows this!
Oh my gosh!!!
Didn't you read the latest PR? 3-71 to the rescue! And don't forget submission for something, somewhere.
Oh I can't wait...Soon, very soon, hope you are as excited as we are, it will be a surprise, soon, very soon, we are going to talk to the regulators.
We will make believe we have something since we still have several who believe. I need to sell 20m more shares at $3 to get us thru the next quarter or two.
Chris is truly worthless and that doesn't say much to those who still believe...
Who has been right? bas and his boy George or kund and bio?
The former likes poop and Pinocchio and the later prognosis has come to past.
If that were the case, shares would be at $1
We all know you are negative, and I get it, but the post to which I'm responding was complete crap
Have been here since 2015 not likely to leave anytime soon!!
Meanwhile, a year from now the 3-71 Phase 2 schizophrenia trial will product some trial data.
But we already know it was significant...the Sept 2023 PR from Anavex (overseen by Dr Jin who has 25 years with FDA as a lead on AD trials) had ADAS COG with a p value of 0.026 i.e 2.26 in a 100 chance that the improvement was due to chance. The FDA draft guidance now states this is the end point they care most about now, not ADL as it's too difficult to show in early AD studies (though Missling did say ADL was trending in right direction in latest call).
LOL!
But of course you HAVE set a timeline in your mind and just watch....YOU will be wrong.
Nothing will happen here for months and months!
Many here have crossed eyed vision, probably from staring too long for a PR on submission.
It ain't happening here soon....No matter what you believe. Chris is full of shit and you are just eating every word...Yum Yum!!
You die hards are just too funny!
He is making it appear that way. Rett is 273 Blacarsimine. If the Results for Rett weren't significant ao why would they be for Alz
Followers
|
1067
|
Posters
|
|
Posts (Today)
|
84
|
Posts (Total)
|
461824
|
Created
|
12/18/07
|
Type
|
Free
|
Moderators RedShoulder Steady_T Bourbon_on_my_cornflakes kund mike_dotcom nidan7500 |
Anavex®Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (“CNS”) diseases, pain and various types of cancer. The Company’s lead compound ANAVEX®2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.
Anavex®Life Sciences’ lead drug candidate, ANAVEX®2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex® a research grant to develop ANAVEX®2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX®2-73 into a Parkinson’s disease clinical trial. ANAVEX®3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions.
The Company is in preparation for ANAVEX®2-73 for a Phase 2/3, placebo-controlled trial in Alzheimer’s disease as well as a Phase 2, placebo-controlled trial in Rett syndrome, for which the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ANAVEX®2-73 and a Phase 2, placebo-controlled trial in Parkinson’s disease.
Headquartered in New York, Anavex® Life Sciences is an American publicly traded corporation on Nasdaq quoted as AVXL
.Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |